
Danish pharmaceutical company Novo Nordisk plans to invest DKK 500m in expanding the company's production facilities near Copenhagen in Denmark, informs the company in a press release Thursday morning.
According to the company, this is to ensure the company's production capacity for the diabetes drug Rybelsus, which is based on the molecule semaglutide.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app